Discovery may help provide clues for fighting and treating HPV
Yale Cancer Center (YCC) scientists have filled in a key gap in understanding the unusual route by which the Human papillomavirus (HPV) infects cells. Their findings, published online today in the journal Cell, may eventually help to broaden the scope of defenses against HPV and provide valuable clues for delivering drugs into cells. HPV is a family of killers. Although there are effective vaccines against these viruses, they still cause about 5% of cancer deaths worldwide, including more than 250,000 women who die of cervical cancer each year.
Program Project Grant Renewed
The National Cancer Institute recently awarded a five-year, $4.7 million program project grant to investigators at Yale School of Medicine to continue studies on the role of viruses in tumorigenic transformation of cells. Virus infection is thought to account for approximately 15% of all human cancers worldwide, and studies of tumor viruses have historically provided insight into basic cellular processes including carcinogenesis, cell cycle control, and signal transduction.
New Simple Proteins Play Active Role in Cellular Function
Yale scientists have developed simple new proteins almost devoid of chemical diversity that still play a surprisingly active and specific role in cellular function, causing cells to act like cancer cells, they report Aug. 10 in the Proceedings of the National Academy of Sciences.
$7.5 Million Grant to Yale Researchers for Role of Viruses in Cancer
The National Cancer Institute recently awarded a five-year, $7.5 million program project grant to investigators at the Yale School of Medicine to continue studies on the role of viruses and mutant cellular proteins in tumorigenic transformation of cells.
Study: Patient’s Genetic Characteristics May Help Differentiate HER2-Low Advanced Breast Cancers and Guide Treatment Selection
In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
Phase 3 Results Offer Hope for Patients With Myelodysplastic Syndromes
Senior author of the study and Yale Cancer Center expert Amer Zeidan , MBBS, says the results showed that imetelstat, a first-in-class telomerase inhibitor, leads to durable red blood cell transfusion independence and a significant improvement in anemia in heavily transfused lower-risk MDS patients.
Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12.
Yale Researchers Develop New Testing Criteria for Hereditary Stomach Cancer
Yale researchers have shown that individuals who carry a mutation in the CDH1 gene have a 30% to 40% risk of developing stomach cancer during their lifetime. Yet many people with the rare inherited condition remain unaware that they have it.
Yale scientists chosen by White House to expedite cancer research
Yale is one of three institutions that have been honored with the White House Cancer Moonshot research grant. Yale's Douglas Hanlon, PhD, research scientist in dermatology, and Richard Edelson, MD, the Anthony N. Brady Professor of Dermatology, describe their groundbreaking research, using mRNA technology to create a vaccine that targets only cancer cells.Source: WTNH News 8
YSPH alumna Margaret Mayer embraces challenge of grant management at the National Cancer Institute
This Alumni Spotlight focuses on Margaret Mayer, PhD ’19 (Chronic Disease Epidemiology), MPH ’16 (Chronic Disease Epidemiology), the program director in the Tobacco Cancer Research Branch at the National Cancer Institute.
Overdiagnosis and Preventative Screening: A Q&A With Ilana Richman
In a Q&A, Ilana Richman, MD, MHS, assistant professor of medicine (general medicine), discusses why overdiagnosis is a concern, the challenges of assessing the benefit of new screening technologies, and the risks and benefits people should weigh when considering preventative screening.
Sang Taek Kim Returns to YSM to Lead Immunotherapy Adverse Events Program
A physician scientist, Sang Taek Kim, MD, PhD, assistant professor of medicine (rheumatology), is interested in the autoimmune complications induced by cancer immunotherapy. In his new role, he serves as director of the Immunotherapy Adverse Events in Rheumatology Program.